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ABSTRACT
Veno-occlusive disease (VOD) of the liver occurs in 10% to 50% of patients after allogeneic stem cell
transplantation, ranging frommild reversible disease to severe disease, with a mortality rate almost always close
to 100%. Recently, promising results in the treatment of established VOD with defibrotide were reported.
Therefore, defibrotide may be used as a prophylactic regimen for hepatic VOD in stem cell transplantation for
hematologic malignancies. Fifty-two successive patients who underwent transplantation between October
1999 and June 2002 received defibrotide prophylaxis intravenously from day 7 to day 20 after transplan-
tation in addition to heparin and were compared with historical controls who underwent transplantation
successively between February 1997 and September 1999. In the defibrotide group, the maximum total
bilirubin levels and the number of patients with serum levels exceeding 50 mol/L were significantly lower
than in the control group (5 of 52 versus 18 of 52, respectively; P  .004). None of the 52 patients developed
VOD (Baltimore criteria), and no side effects occurred. These results were significantly different (P  .001)
from controls (10/52 [19%] with VOD, 3 of whom died of severe VOD). In addition, day 100 event-free survival
was significantly higher in the study group (P  .02), with a trend toward better day 100 overall survival (P 
.07). These results suggest that defibrotide given in addition to heparin may be an efficient prophylaxis for VOD.
© 2004 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Veno-occlusive disease (VOD) of the liver is one
f the complications of regimen-related toxicity that
an occur after hematopoietic stem cell transplanta-
ion (HSCT) [1,2]. Clinical manifestations of VOD
re jaundice, weight gain caused by ﬂuid retention,
scites, and painful hepatomegaly. The reported inci-
ence after HSCT varies widely between 0% and
0%, depending on the series [2]. This disparity is
robably due to heterogeneity in the deﬁnition of
OD, various risk factors identiﬁed, and small num-
ers of patients studied. The condition ranges in se-
erity from a mild, reversible form to a severe syn-
rome associated with multiple organ failure and t
B&MTeath [2]. Twenty to ﬁfty percent of these patients die
f VOD [3], and in established severe VOD, the death
ate is close to 100% by day 100 after HSCT [4].
VOD is caused by damage to sinusoidal endothe-
ial cells and hepatocytes in zone 3 of the liver acinus
urrounding the central veins [5-8]. The initial events
re deposition of factor VIII and ﬁbrinogen within the
enular walls and sinusoid [7], followed by progressive
enular occlusion that ultimately leads to widespread
iver disruption [5,8]. More recent studies have sug-
ested that sinusoidal endothelial cells are the primary
ite of the toxic injury, which leads to impairment of
he microcirculation, and that the clinical and physi-
logic ﬁndings are more consistent with sinusoidal
han with venular obstruction [9]. This has led to a
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3ew name for this type of liver injury: sinusoidal ob-
truction syndrome [10]. Thus, in certain patients
such as those with prior exposure to gemtuzumab
zogamicin), clinical and pathophysiologic ﬁndings
re more consistent with sinusoidal obstruction as a
redominant feature (versus venular and hepatocellu-
ar injury), but until prospective multicenter studies
how otherwise, the established terminology of VOD
as yet to be superseded by sinusoidal obstruction
yndrome. During this period of toxic injury, a pro-
oagulant state is present, with low plasma levels of
ntithrombin III and protein C, consumption of factor
II, and increased levels of plasminogen activator
nhibitor-1 [11]. In addition, increased levels of von
illebrand factor multimers and refractoriness to
latelet transfusion suggest ongoing endothelial injury
12]. Finally, hepatocellular necrosis and vascular oc-
lusion lead to hepatorenal pathology, multiorgan fail-
re, and death.
Several agents (heparin, low-molecular-weight
eparin, ursodiol, prostaglandin E1, and pentoxifyl-
ine) have been evaluated without clear demonstration
f satisfactory results [3,13-18]. Deﬁbrotide, which
as antithrombotic, anti-ischemic, anti-inﬂammatory,
nd thrombolytic properties, has recently shown some
fﬁcacy in the treatment of moderate to severe VOD.
ifty-ﬁve percent complete resolution without signif-
cant toxicity has been reported in European studies in
hich patients treated with deﬁbrotide had moderate
r severe disease [19], and this was lower at 35% to
0% of patients with multiorgan failure in American
tudies focusing on severe VOD [20,21]. Prompted by
hese encouraging data, we decided to investigate pro-
pectively whether deﬁbrotide could be used in the
rophylactic setting. We report the experience of a
ingle center where 52 consecutive patients received
eﬁbrotide as VOD prophylaxis during allogeneic
tem cell transplantation for various hematologic malig-
ancies. These were compared with 52 historical con-
rol patients, who underwent transplantation in the
one marrow transplantation (BMT) unit just before
he study and received heparin alone as prophylaxis.
ATERIALS AND METHODS
atients
Between October 1999 and June 2002, 52 succes-
ive patients with hematologic malignancies under-
ent allogeneic peripheral blood stem cell (PBSC) or
MT and received deﬁbrotide as VOD prophylaxis in
he PBSC/BMT unit of the Geneva University Hos-
ital. All patients gave their informed consent, and all
he research studies were approved by the university
nd the institutional review boards. The patients in
he study were compared with historical control group
f 52 patients who had successively undergone trans- C
48lantation in our center just before the study (between
ebruary 1997 and September 1999) and received
nly heparin.
linical Monitoring
VOD prophylaxis with deﬁbrotide (Prociclide;
rinos, Como, Italy) 200 to 400 mg (10-25 mg/kg/d
n children weighing 30 kg) intravenously (IV) in nor-
al saline over 2 hours 4 times daily was initiated the
ay before the conditioning regimen was started and
ontinued until posttransplantation day 20. Patients at
igher risk of developing VOD, such as those with
retransplantation liver disturbance, pretransplanta-
ion abdominal irradiation, or previous stem cell
ransplantation [1,22,23], received the higher dose
400 mg 4 times daily), as compared with standard
oses (200 mg 4 times daily) in standard-risk patients.
n addition, low-dose heparin (5000 IU IV continu-
usly for 24 hours if weight 70 kg or 10000 IU if
eight 70 kg) was given routinely [13]. Patients
ere examined and their weight was recorded daily.
hey were evaluated for the presence or absence of
nexplained weight gain, liver pain, hepatomegaly,
nd ascites and for toxicities known to be related to
eﬁbrotide [20]. In case of suspicion of VOD devel-
pment, ultrasonography with a Doppler test was per-
ormed to evaluate the liver, the presence of ascites,
nd attenuated or inverted hepatic ﬂow.
Laboratory tests included daily complete blood
ount and electrolytes, and, 3 times per week, liver
unction tests aspartate aminotransferase, alanine ami-
otransferase, alkaline phosphatase, direct and indi-
ect bilirubin, -glutamyltransferase, prothrombin
ime (PT), activated partial thromboplastin time
aPTT), and ﬁbrinogen.
valuation of VOD
We used the Baltimore criteria for diagnosis of
OD–jaundice (bilirubin level 34.2 mol/L) and 2
r more of the following: hepatomegaly, right upper
uadrant pain, ascites, and unexplained weight gain
5% above baseline weight) [24].
onditioning Regimens
Most patients (n  38) received cyclophospha-
ide (Cy) combined with fractionated total body ir-
adiation (TBI) (Cy, 60 mg/kg IV day 6 and 5;
BI, 1000 cGy for patients40 years old or 1200 cGy
or patients 40 years old in fractionated doses twice
aily, day3 to1) [25] with or without methylpred-
isolone (MP) (n 26) with or without antithymocyte
lobulin (ATG) (n  10). Three patients received
P-16 (60 mg/kg) combined with TBI and MP.
hree patients received a busulfan (Bu)–based regi-
en (Bu, 1 mg/kg orally every 6 hours day 7 to 4;
y, 60 mg/kg/d IV days 3 and 2) with or without
M
r
r
ﬂ
t
p
d
m
t
P
i
1
b
p
h
m
m
F
n
m
c
G
(
(
1
c
[
o
h
b
f
W
a
G
t
o
S
s
S
p
T
N
M
S
D
R
B
P
C
G
C
T
I
C
*
†
Defibrotide May Prevent VOD after Allogeneic BMT
BP (n 1) with or without ATG (n 1). One patient
eceived Cy combined with VP-16. Seven patients
eceived a reduced-intensity conditioning regimen, 6
udarabine based and 1 with TBI at 200 cGy). Pa-
ients receiving Bu were given clonazepam as seizure
rophylaxis. Uroepithelial prophylaxis with hyperhy-
ration and continuous perfusion of mesna was ad-
inistered during Cy infusion and for 24 hours after
he last dose of Cy.
BSC or BMT (Study Group)
Thirty patients received PBSC from an HLA-
dentical sibling, 2 patients received PBSC from a
-antigen-mismatched relative, and 1 patient received
oth marrow and peripheral blood from a histocom-
atible sibling. Three patients received marrow from a
istocompatible sibling. Twelve patients received
arrow from an unrelated donor; 8 pairs were
atched, and 4 pairs were 1-antigen mismatched.
our patients received PBSC from an unrelated do-
or; 3 pairs were matched, and 1 pair was 1-antigen
ismatched. Bone marrow was plasma and erythro-
able 1. Patient Characteristics
Characteristic
Stud
(with D
o. Patients
edian age, y (range) 36.5
ex (M/F) 2
iagnosis
CML
AML
ALL
MDS
Lymphoma
AA
MM
isk status (SR/HR) 2
MT (RD/UD) 3
BSC/BM/CB 37
omplete T-dep/Partial T-dep/no T-dep 9/
VHD prophylaxis
CsAMTX/CsA/other 35
onditioning regimen
With cyclophosphamide
With busulfan
With VP-16
RIC
BI doses (1200/1000/600/200/0 cGy) 28/1
ncreased transaminases before conditioning 7/52
ML indicates chronic myeloid leukemia; AML, acute myeloid leu
AA, aplastic anemia; MM, multiple myeloma; SR, standard risk
chronic phase 1 or with AA); HR, high risk (all others); BMT,
PBSC, peripheral blood stem cell; BM, bone marrow; CB, cord
conditioning; TBI, total body irradiation; T-dep, T-cell depleti
P value calculated by the Fisher exact test or Mann-Whitney test.
Statistically signiﬁcant.yte depleted (Table 1). s
B&MTraft-versus-Host Disease Prophylaxis
Study Group)
Details of the different graft-versus-host disease
GVHD) prophylaxis regimens are outlined in Table
. Most patients received cyclosporine and short-
ourse methotrexate with or without other agents
26,27]. Most patients also had complete (9 patients)
r partial (32 patients) T-cell depletion in vitro with
umanized anti-CD52 (CAMPATH-1H, produced
y Therapeutic Antibody Centre, University of Ox-
ord, UK; courtesy of Geoff Hale and Hermann
aldmann) (Table 1) [28]. Treatment of established
cute GVHD was with high-dose MP; those with
VHD resistant to MP received ATG, either anti-
hymocyte gamma globulin (Upjohn, Kalamazoo, MI)
r ATG-Fresenius (Fresenius Medical Care AG,
tans, Switzerland): GVHD was graded according to
tandard criteria [29].
upportive Care
Patients were treated at the Bone Marrow Trans-
lant Unit of the Geneva University Hospital in a
p
ide)
Historical Control Group
(without Defibrotide) P Value*
52
37 (4-60) .82
38/14 .07
.84
12
14
12
4
5
3
2
28/24 .1
43/9 .17
37/14/1 .82
16/14/22 .002†
23/28/1 .03†
38 .49
11 .61
10 .26
3 .32
38/0/1/0/13 .22
6/52 (12%) .77
ALL, acute lymphoid leukemia; MDS, myelodysplastic syndrome;
ts with acute leukemia in ﬁrst complete remission, with CML in
arrow transplantation; RD, related donor, UD, unrelated donor;
; CsA, cyclosporin A; MTX, methotrexate; RIC, reduced-intensityy Grou
efibrot
52
(5-60)
8/24
16
13
10
7
4
0
2
2/30
6/16
/15/0
32/11
/15/2
42
8
5
7
4/0/1/9
(13%)
kemia;
(patien
bone m
blood
on.ingle isolation room with laminar air ﬂow. Perma-
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3ent central catheters (Groshong, Bard Medica SA,
eneva, Switzerland) were used routinely. Empiric IV
ntibiotics, liposomal amphotericin B (Ambisome,
resenius Medical Care AG, Stans, Switzerland), acy-
lovir, cytomegalovirus (CMV)–negative blood prod-
cts, and total parenteral nutrition were given as re-
uired. Fungal prophylaxis was with ﬂuconazole IV
00 mg/d. Patients were screened twice per week for
MV by pp65 assay, and, on positive ﬁndings, pre-
mptive ganciclovir therapy was given at 5 mg/kg IV
wice daily for 14 days and then 5 mg/kg daily or, as
djusted for renal impairment, for 2 weeks or longer in
ase of persistent CMV antigenemia [30]. In case of
eutropenia, foscarnet was given at 90 mg/kg IV twice
aily for 2 weeks and then 90 mg/kg daily or, as
djusted for renal impairment, for 2 weeks or longer in
ase of persistent CMV antigenemia. Growth factors
ere used for graft failure, drug-induced neutropenia,
nd persistent febrile neutropenia.
tatistical Analysis
Overall survival (OS) and event-free survival
EFS) (events were deﬁned as the ﬁrst appearance of
OD, acute GVHD [aGVHD] grade II, relapse,
r death), treatment-related mortality (TRM), re-
apse, and aGVHD probabilities were calculated
ith the product limit method of Kaplan and Meier
31]. Surviving patients were censored on January
2, 2003. Categorical variables and VOD incidence
etween the study group and the historical control
roup were compared by using the 2 test or Fisher
xact test, as appropriate; continuous variables were
ompared by using the Mann-Whitney test, and
urvival data were analyzed by the log-rank test.
ariables are described by means of median and ﬁrst
nd third quartiles.
able 2. Comparison between the Study Group and the Control Group
Parameter
Study Group
(S)
aximum total bilirubin† (mol/L) 17 (14; 23)
o. patients with total bilirubin >50
mol/L (%) 5/52 (10%)
aximum aPTT (s) 31.3 (28.7; 33.9)
o. patients with maximum aPTT >50 s 1/52 (2%)
aximum PT (INR) 1.1 (1.1; 1.3)
o. patients with maximum PT >1.5 INR 0/52 (0%)
aximum fibrinogen (g/L) 6.2 (5.3; 7.9)
o. patients with maximum fibrinogen
>6 g/L 29/52 (56%)
PTT indicates activated partial thromboplastin time; PT, prothro
ilirubin levels were observed for the ﬁrst 100 days.
P value calculated by the Mann-Whitney test or Fisher exact test.
Values are given as median and ﬁrst and third quartiles.
50ESULTS
atient Characteristics
The characteristics of the patients are shown in
able 1. The 2 groups were similar with respect to
ge, primary disease, conditioning regimen, risk fac-
ors for VOD, hemoglobin level, and history of liver
ysfunction (data not shown), with some imbalance
egarding sex (more men in the control group), risk
tatus (more high risk in the study group), and type of
ransplant (more unrelated donors in the study group).
ethotrexate was given as GVHD prophylaxis more
requently in the study group. Patients in the study
roup had undergone transplantation less frequently
ith grafts from which the T cells had been removed
ompletely (9 versus 16 in the control group), more
requently with partially T cell–depleted grafts (32
ersus 14 patients in the control group), and less
requently without T-cell depletion (11 versus 22 pa-
ients in the control group).
ide Effects
Deﬁbrotide was well tolerated and did not have to
e discontinued in any of the patients. There was no
rade 3 or 4 toxicity related to deﬁbrotide or any
orsening of clinical bleeding. Mild to moderate tox-
city such as mild nausea, fever, and abdominal cramps
as documented, but it was difﬁcult to determine
hether it was directly attributable to deﬁbrotide or to
he conditioning or other drugs commonly used dur-
ng transplantation.
ncidence of VOD
In the study group, none of the patients developed
OD, according to the criteria of Jones et al. [24].
his was signiﬁcantly different (P  .001) from the
ontrol group, in which 10 of 52 patients had VOD
without Patients with VOD
trol Group
(C)
P Value,
S versus C*
Control Group
without VOD
(C1)
P Value,
S versus C1
(19; 81) <.0001 29 (16; 44) .002
(35%) .004 9/42 (21%) .15
(30.9; 46.9) .002 34.7 (30.2; 47.3) .02
(19%) .008 8/42 (19%) .01
(1.1; 1.4) .002 1.2 (1.1; 1.4) .02
(12%) .03 3/42 (7%) .09
(5.7; 8.5) .05 7.1 (5.6; 8.5) .06
(75%) .06 31/42 (74%) .09
ime; INR, international normalized ratio.with or
Con
33
18/52
35.4
10/52
1.2
6/52
7.1
39/52
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BVOD was the cause of death in 3 patients, 1 of which
as autopsy proven; for the 2 others, autopsy was
enied). It is noteworthy that none of the 4 women in
he control group who developed VOD had been
igure 1. A, Event-free survival (EFS) and B, overall survival (OS)
fter allogeneic stem cell transplantation in patients treated with
eﬁbrotide prophylaxis (●) or without ().
able 3. Comparison of Survival between Patients with and without D
Parameter Study Group
ay 100 EFS 65% (CI, 52%-77%)
ay 100 OS 92% (CI, 82%-97%)
FS (1 y) 46% (CI, 32%-59%)
S (1 y) 81% (CI, 67%-89%)
RM (1 y) 14% (CI, 7%-27%)
R (1 y) 20% (CI, 11%-35%)
GVHD grade >II 34% (CI, 21%-52%)
FS indicates event-free survival; OS, overall survival; TRM, treatm
disease; CI, 95% conﬁdence interval.
P value calculated by the log-rank test.
Statistically signiﬁcantly different from the control group.
B&MTreated with norethisterone, which is known to in-
rease the incidence of VOD [32]. Table 2 shows that
he maximum level of total bilirubin up to 100 days
fter transplantation and the percentage of patients
ith a total bilirubin 50 mol/L were signiﬁcantly
ower (P  .0001 and P  .004, respectively) in the
roup treated with deﬁbrotide. The protective effect
f deﬁbrotide was also evident in that the 42 control
atients without clinically manifest VOD had signiﬁ-
antly (P  .02) higher levels of total bilirubin than
he study patients. In addition, the parameters linked
o clot formation on damaged endothelial cells were
ess manifest in the group treated with deﬁbrotide.
he aPTT and PT were signiﬁcantly lower in the
tudy group (P  .002 for both variables). As a result,
he number of patients with an aPTT 50s or a PT
1.5 international normalized ratio was signiﬁcantly
ower (P  .008 and P  .03, respectively). In addi-
ion, maximum ﬁbrinogen levels were marginally
ower (P  .05) in the patients treated with deﬁb-
otide. With the exception of the ﬁbrinogen levels and
umber of patients with PT 1.5, all these effects
emained signiﬁcant, but at a reduced level (P  .02),
fter the patients with VOD in the control group were
mitted from the analysis (Table 2).
S, EFS, Relapse, TRM, and Incidence of GVHD
Figure 1 shows the EFS (Figure 1A) and OS (Fig-
re 1B) of the patients in the deﬁbrotide group and in
he control group. The median follow-up was 21
onths (range, 9-41 months) for patients treated with
eﬁbrotide and 57 months (range, 43-70 months) for
atients of the control group. Up to day 100 after
ransplantation, the EFS was signiﬁcantly higher in
he group treated with deﬁbrotide (P  .02; Table 3),
lthough a trend (P  .06) toward better EFS was still
isible when the patients with VOD were omitted
rom the analysis. The effect of the deﬁbrotide pro-
hylaxis on EFS was noticeable only as a trend (P 
07) in the ﬁrst year. In addition, there was a trend
oward better day 100 survival in the deﬁbrotide
roup (P  .07; Figure 1B; Table 3), with a better OS
e Prophylaxis
Control Group P Value*
44% (CI, 32%-58%) .02†
81% (CI, 68%-89%) .07
33% (CI, 22%-46%) <.07
62% (CI, 48%-74%) .03†
28% (CI, 17%-42%) .075
29% (CI, 17%-44%) .25
38% (CI, 24%-57%) .58
lated mortality; RR, relapse rate; aGVHD, acute graft-versus-hosteﬁbrotid
ent-re351
a
T
a
(
T
d
d
D
b
t
w
1
d
d
c
c
(
t
a
s
g
a
t
m
r
i
a
t
p
d
5
b
V
c
w
p
s
f
f
c
l
w
w
w
s
f
A
G
m
(
w
t
a
s
V
w
o
f
t
b
a
t
t
p
.
o
s
n
a
o
t
w
t
b
s
d
o
t
t
t
p
T
V
I
G
G
R
P
I
S
G
Y. Chalandon et al.
3t 1 year (P  .03). There was also a trend to less
RM (P  .075) in the study group (causes of death
re shown in Table 4), and the occurrence of aGVHD
P  .6) did not differ between groups (Table 3).
herefore, the improvement in EFS and OS seems
irectly linked to the decrease in VOD resulting from
eﬁbrotide prophylaxis.
ISCUSSION
VOD is a common complication after allogeneic
lood or marrow stem cell transplantation. Most of
he time, patients with mild or moderate disease do
ell, with a predicted survival of 77% to 91% at day
00. In contrast, patients with severe disease have a
ismal outcome, with an expected survival of 2% at
ay 100 [33]. Unfortunately, the diagnosis remains
omplicated because of a lack of consensus regarding
lassiﬁcation of the different stages of the disease
mild, moderate, and severe) [3]. For the same reason,
he interpretation of studies on prophylactic or ther-
peutic drugs is problematic.
Recently, some progress has been made in treating
evere VOD with recombinant tissue-type plasmino-
en activator [34] or deﬁbrotide [19-21]. However,
lthough recombinant tissue-type plasminogen activa-
or was associated with a response rate of approxi-
ately 30%, it has been associated with a concordant
isk of severe, life-threatening, and fatal hemorrhage
n a similar proportion. Deﬁbrotide was in fact used as
n alternative approach because the side effect of sys-
emic bleeding was thought to be markedly less, which
roved to be the case [19-21]. Because it may be
ifﬁcult to improve the complete response of 25% to
5% obtained in these studies, we have tested the
eneﬁt of deﬁbrotide as a prophylactic agent for
OD. In our nonrandomized series, no VOD oc-
urred in 52 successive allogeneic transplant patients
ho received deﬁbrotide as prophylaxis. This com-
ared favorably to the historical control series of 52
uccessive patients who underwent transplantation be-
ore the study, 10 of whom developed VOD that was
atal in 3 cases. The high incidence of VOD in the
able 4. Cause of Death for Patients in the Study and Control Groups
Cause of Death Survival Time, Study Group (
OD
nfection 24, 47, 32
VHD  infection 442, 203
VHD 164, 74
elapse or progression 742, 113, 305, 392, 191
ulmonary toxicity
nterstitial pneumonitis
udden death 159
VHD indicates graft-versus-host disease.ontrol group is comparable to other recently pub- r
52ished reports (15%-29%) [35-37]. Although the study
as not randomized, we consider these results note-
orthy because the control group consisted of patients
ho successively underwent transplantation in the
ame center with clinical characteristics not very dif-
erent from those of the patients in the study group.
lthough the study group received more aggressive
VHD prophylaxis, this was counterbalanced by
ore efﬁcient T-cell depletion in the control group
Table 1). Consequently, the occurrence of GVHD
as identical for both groups (Table 3), which led us
o believe that the differences in GVHD prophylaxis
nd T-cell depletion between groups did not cause a
igniﬁcance bias with regard to the risk of VOD.
The study shows that not only the incidence of
OD (P  .001), but also the day 100 EFS (P  .02),
ere signiﬁcantly different (Figure 1A). In contrast,
nly a trend to a better day 100 OS (P  .07) was
ound, possibly owing to the low number of patients in
he study or to the low incidence of mortality caused
y VOD. Further trends were found for a better
ctuarial 1-year EFS and OS (P  .07 and .03, respec-
ively). These improvements were possibly related to
he decrease in VOD incidence after deﬁbrotide pro-
hylaxis because a trend toward decreased TRM (P 
075) was found without differences in the incidence
f GVHD or in the relapse rate. It is obvious that the
tatistically signiﬁcant improvement in OS at 1 year is
ot due to the decrease in the number of VOD deaths
lone. Had this been the case, with the VOD deaths
ccurring during the ﬁrst 100 days after transplanta-
ion, the better day 100 OS, visible only as a trend,
ould have been even more signiﬁcant. It is possible
hat the VOD prophylaxis had more general effects,
ut we believe that these discrepancies just reﬂect the
tatistics in small groups of patients and that both the
ay 100 OS (P  .07) and the 1-year OS (P  .03) are
f the same, perhaps borderline, signiﬁcance.
In the study group, the median value of maximum
otal bilirubin and the percentage of patients with a
otal bilirubin 50 mol/L were signiﬁcantly lower
han in the control group, which resulted in fewer
atients with severe liver problems. This might be
Survival Time, Control Group (d)
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Bnd sinusoids, a complication that generates postsinu-
oidal intrahepatic portal hypertension, which is fre-
uently observed in patients who develop VOD
38,39].
Although the pathogenesis of VOD is not yet
ompletely understood, the congestion may be trig-
ered by endothelial injury in sinusoids and hepatic
enules caused by the conditioning regimen [1,6]. The
ndothelial damage induces a local hypercoagulable
tate by activating the coagulation cascade and favor-
ng clot formation over natural anticoagulation via
ownregulation of thrombomodulin and release of
on Willebrand factor. Several authors have observed
hat in patients with VOD, the levels of coagulation
roteins and naturally occurring anticoagulants are
ltered (decreased protein C and antithrombin III and
ncreased factor VIII and ﬁbrinogen).
However, none of these parameters was useful for
redicting VOD or conﬁrming its diagnosis. Recently,
t has been shown that PT and aPTT can differentiate
etween mild and severe VOD [36]. Therefore, with
ts known capacity to modulate endothelial injury,
eﬁbrotide may function through the interruption of
lot formation, a hypothesis supported by the almost
ormal values of PT, aPTT, and ﬁbrinogen in the
tudy group, although this is not thought to be the
redominant effect of deﬁbrotide but rather to favor-
bly affect endothelial cell injury—in particular, mi-
rovascular damage [40,41].
A further 48 patients have undergone transplanta-
ion in our unit with deﬁbrotide prophylaxis, and none
eveloped VOD (unpublished data), thus emphasizing
hese results.
In conclusion, the data suggest that deﬁbrotide
ay prevent VOD after allogeneic stem cell trans-
lantation and justify a randomized clinical trial to
stimate its real effect.
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